KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Part of paid clinical trials in Canton, Ohio.

Sponsor
Gabrail Cancer Center Research
Study ID
NCT02250885
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Neuroendocrine

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Selinexor — DRUG
    Selective Inhibitor fo Nuclear Export (SINE)

Study Details

Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.

Key Dates

Start date
Aug 31, 2014
Status verified
Sep 2019
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Selinexor (KPT-330)
    Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.

Primary Outcome Measure

Overall Response Rate [ Time Frame: Every 8 weeks from screening until documented disease progression or date of death, whichever occurs first, up to approximately 100 months. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Gabrail Cancer Center ResearchCantonOhio44718-

Find similar trials in Canton, OH

By research site
Gabrail Cancer Center Research· Canton, OH

Related Studies